Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: Strategies for clinical application

Future Oncology

Volumn 3, Issue 5, 2007, Pages 545-556

  Smith, Kerrington D ^a   Shao, Michael Y ^b   Posner, Mitchell C ^b   Weichselbaum, Ralph R ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c MC 9006   (United States)

Author keywords

134.5; HSV 1; Mitogen activated protein kinase kinase; Oncolytic virotherapy

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE; G 207; HSV 1716; IMMUNOMODULATING AGENT; MITOGEN ACTIVATED PROTEIN KINASE; NV 1020; ONCOLYTIC HERPES VIRUS; PROTEIN KINASE R; R 3616; R 7020; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADAPTIVE IMMUNITY; CANCER THERAPY; CELL SPECIFICITY; CELL TYPE; CYTOLYSIS; ENZYME ACTIVATION; GENE DELETION; GENOTYPE; HERPES SIMPLEX VIRUS 1; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SOLID TUMOR; TUMOR; TUMOR BIOPSY; TUMOR CELL; TUMOR CELL DESTRUCTION; VIRUS ATTENUATION; VIRUS MUTANT; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; GENOTYPE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; MAP KINASE KINASE KINASES; MUTATION; NEOPLASMS; ONCOLYTIC VIROTHERAPY; SEQUENCE DELETION;

EID: 35348976180     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.3.5.545     Document Type: Review

References (74)

1. 134.5 gene of herpes simplex virus. J. Virol. 68, 8304-8311 (1994).
2. Andreansky S, Soroceanu L, Flotte ER et al.: Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57, 1502-1509 (1997).
3. Bennett JJ, Delman KA, Burt BM et al.: Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther. 9, 935-945 (2002).
4. Chung SM, Advani SJ, Bradley JD et al.: The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther. 9, 75-80 (2002).
5. Smith KD, Mezhir JJ, Bickenbach K et al.: Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Δγ(1)34.5 mutants of herpes simplex virus 1. J. Virol. 80, 1110-1120 (2006).
6. Levaditi C, Nicolau S: Affinite du virus herpetique pour les neoplasms epitheliaux. Compt. Rend. Soc. De Biol. 86, 498-500 (1922).
7. Moore AE: Effect of inoculation of viruses influenza A and Herpes simplex on the growth of transplantable tumors in mice. Cancer 2, 516-524 (1949).
8. 134.5, a gene nonessential for growth in culture. Science 250, 1262-1266 (1990).
9. Chou J, Roizman B: The γ 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shuroff of protein synthesis characteristic of programed cell death in neuronal cells. Proc. Natl Acad. Sci. USA 89, 3266-3270 (1992).
10. Metz DH, Esteban M: Interferon inhibits viral protein synthesis in L cells infected with vaccinia virus. Nature 238, 385-388 (1972).
11. Friedman RM, Metz DH, Esteban RM, Tovell DR, Ball LA, Kerr IM: Mechanism of interferon action: inhibition of viral messenger ribonucleic acid translation in L-cell extracts. J. Virol. 10, 1184-1198 (1972).
12. Kerr IM, Brown RE, Ball LA: Increased sensitivity of cell-free protein synthesis to double-stranded RNA after interferon treatment. Nature 250, 57-59 (1974).
13. Roberts WK, Hovanessian A, Brown RE, Clemens MJ, Kerr IM: Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis. Nature 264, 477-480 (1976).
14. Galabru, J, Hovanessian AG: Two interferon-induced proteins are involved in the protein kinase complex dependent on double-stranded RNA. Cell 43, 685-694 (1985).
15. Krust B, Galabru J, Hovanessian AG: Further characterization of the protein kinase activity mediated by interferon in mouse and human cells. J. Biol. Chem. 259, 8494-8498 (1984).
16. Dey M, Cao C, Dar AC et al.: Mechanistic link between PKR dimerization, autophosphorylation, and eIF2α substrate recognition. Cell 122, 901-913 (2005).
17. Dar AC, Dever TE, Sicheri F: Higher-order substrate recognition of eIF2α by the RNA-dependent protein kinase PKR. Cell 122, 887-900 (2005).
18. Farrell PJ, Balkow K, Hunt T, Jackson RJ, Trachsel H: Phosphorylation of initiation factor elF-2 and the control of reticulocyte protein synthesis. Cell 11, 187-200 (1977).
19. He B, Gross M, Roizman B: The γ(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1α to dephosphorylate the α subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc. Natl Acad. Sci. USA 94, 843-848 (1997).
20. Honess RW, Roizman B: Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J. Virol. 14, 8-19 (1974).
21. Chou J, Chen JJ, Gross M, Roizman B: Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2α and premature shutoff of protein synthesis after infection with γ 134.5- mutants of herpes simplex virus 1. Proc. Natl. Acad. Sci. USA 92, 10516-10520 (1995).
22. Gale M Jr, Katze MG: Molecular mechanisms of interferon resistance mediated by viral-directed inhibition of PKR, the interferon-induced protein kinase. Pharmacol. Ther. 78, 29-46 (1998).
23. Leib DA, Machalek MA, Williams BR, Silverman AH, Virgin HW: Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc. Natl. Acad. Sci. USA 97, 6097-6101 (2000).
24. Chee AV, Roizman B: Herpes simplex virus 1 gene products occlude the interferon signaling pathway at multiple sites. J. Virol. 78, 4185-4196 (2004).
25. 134.5 protein of herpes simplex virus 1 are required for viral resistance to interferon-α/β. Virology 290, 115-120 (2001).
26. Sundaresan P, Hunter WD, Martuza RL, Rabkin SD: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J. Virol. 74, 3832-3841 (2000).
27. 134.5-deleted herpes simpler virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity. Cancer Res. 67, 8301-8306 (2007).
28. Meignier B, Martin B, Whitley RJ, Roizman B: In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162, 313-321 (1990).
29. Hunter WD, Martuza RI, Feigenbaum F et al.: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J. Virol. 73, 6319-6326 (1999).
30. Rampling R, Cruickshank G, Papanastassiou V et al.: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859-866 (2000).
31. Markert JM, Medlock MD, Rabkin SD et al.: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. 7, 867-874 (2000).
32. Kemeny N, Brown K, Covey A et al.: Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum. Gene Ther. 17, 1214-1224 (2006).
33. Ejercito PM, Kieff ED, Roizman B: Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J. Gen. Virol. 2, 357-364 (1968).
34. Clemens MJ: Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 23, 3180-3188 (2004).
35. Meurs EF, Galabru J, Barber GN, Katze MG, Hovanessian AG: Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase. Proc. Natl Acad. Sci. USA 90, 232-236 (1993).
36. Barber GN, Wambach M, Thompson S, Jagus R, Katze MG: Mutants of the RNA-dependent protein kinase (PKR) lacking double-stranded RNA binding domain I can act as transdominant inhibitors and induce malignant transformation. Mol. Cell. Biol. 15, 3138-3146 (1995).
37. Barber GN, Jagus R, Meurs EF, Hovanessian AG, Katze MG: Molecular mechanisms responsible for malignant transformation by regulatory and catalytic domain variants of the interferon-induced enzyme RNA-dependent protein kinase. J. Biol. Chem. 270, 17423-17428 (1995).
38. Jacquemont B, Roizman B: RNA synthesis in cells infected with herpes simplex virus. X. Properties of viral symmetric transcripts and of double-stranded RNA prepared from them. J. Virol. 15, 707-713 (1975).
39. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA: Creation of human tumour cells with defined genetic elements. Nature 400, 464-468 (1999).
40. Farassati F, Yang AD, Lee PW: Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol. 3, 745-750 (2001).
41. Ito T, Jagus R, May WS: Interleukin 3 stimulates protein synthesis by regulating double-stranded RNA-dependent protein kinase. Proc. Natl Acad. Sci. USA 91, 7455-7459 (1994).
42. Le Gall M, Chambard JC, Breittmayer JP, Grall D, Pouyssegur J, Van Obberghen-Schilling E: The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal. Mol. Biol. Cell 11, 1103-1112 (2000).
43. Shimamura A, Ballif BA, Richards SA, Blenis J: Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr. Biol. 10, 127-135 (2000).
44. von Gise A, Lorenz P, Wellbrock C et al.: Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol. Cell. Biol. 21, 2324-2336 (2001).
45. Ballif, BA, Blenis J: Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ. 12, 397-408 (2001).
46. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331 (1995).
47. Pouyssegur J, Volmar V, Lenormand P: Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling. Biochem. Pharmacol. 64, 755-763 (2002).
48. Hoshino R, Chatani Y, Yamori T et al.: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813-822 (1999).
49. Davies H, Bignell GR, Cox C et al.: Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
50. Sebolt-Leopold JS, Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937-947 (2004).
51. Luker GD, Bardill JP, Prior JL, Pica CM, Piwnica-Worms D, Leib DA: Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J. Virol. 76, 12149-12161 (2002).
52. Yamamoto S, Deckter LA, Kasai K, Chiocca EA, Saeki Y: Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors. Gene Ther. 13, 1731-1736 (2006).
53. Mezhir JJ, Advani SJ, Smith KD et al.: Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses. Cancer Res. 65, 9479-9484 (2005).
54. Kuruppu D, Tanabe KK: Viral oncolysis by herpes simplex virus and other viruses. Cancer Biol. Ther. 4, 524-531 (2005).
55. Esclarine A, Taddeo B, Evans L, Roizman B: The herpes simplex virus 1 UL41 gene-dependent destabilization of cellular RNAs is selective and may be scquence-specific. Proc. Natl Acad. Sci. USA 101, 3603-3608 (2004).
56. Mohr I, Gluzman Y: A herpesvirus genetic element which affects translation in the absence of the viral GADD34 function. EMBO J. 15, 4759-4766 (1996).
57. Cassady KA, Gross M, Roizman B: The herpes simplex virus US11 protein effectively compensates for the γl (34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the α subunit of eukaryotic translation initiation factor 2. J. Virol. 72, 8620-8626 (1998).
58. Mohr I, Sternberg D, Ward S, Leib D, Mulvey M, Gluzman Y: A herpes simplex virus type 1 γ34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals. J. Virol. 75, 5189-5196 (2001).
59. Shah AC, Parker JN, Gillespie GY et al.: Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther. 14, 1045-1054 (2007).
60. Advani SJ, Weichselbaum RR, Whitley RJ, Roizman B: Friendly fire: redirecting herpes simplex virus- 1 for therapeutic applications. Clin. Microbiol. Infect. 8, 551-563 (2002).
61. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL: Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. 10, 2237-2243 (1999).
62. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E: Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 3, 19 (2003).
63. Kuruppu D, Brownell AL, Zhu A et a.: Positron emission tomography of herpes simplex virus 1 oncolysis. Cancer Res. 67, 3295-3300 (2007).
64. Xu F, Sternberg MR, Kottiri BJ et al.: Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296, 964-973 (2006).
65. Ikeda K, Wakimoto H, Ichikawa T et al.: Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. 74, 4765-4775 (2000).
66. Da Costa XJ, Brockman MA, Alicot E et a.: Humoral response to herpes simplex virus is complement-dependent. Proc. Natl Acad Sci. USA 96, 12708-12712 (1999).
67. Wakimoto H, Ikeda K, Abe T et al.: The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 5, 275-282 (2002).
68. Verschoor A, Brockman MA, Knipe DM, Carroll MC: Cutting edge: myeloid complement C3 enhances the humoral response to peripheral viral infection. J. Immunol. 167, 2446-2451 (2001).
69. Ikeda K, Ichikawa T, Wakimoto H et al.: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881-887 (1999).
70. Leib DA, Harrison TE, Laslo KM, Machalek MA, Moorman NJ, Virgin HW: Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo. J. Exp. Med. 189, 663-672. (1999).
71. Yokota S, Yokosawa N, Kubota T et al.: Herpes simplex virus type 1 suppresses the interferon signaling pathway by inhibiting phosphorylation of STATs and janus kinases during an early infection stage. Virology 286, 119-124 (2001).
72. Delman KA, Bennett JJ, Zager JS et al.: Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum. Gene Ther. 11, 2465-2472 (2000).
73. Schellingerhout D, Bogdanov A Jr, Marecos E, Spear M, Breakefield X, Weissleder R: Mapping the in vivo distribution of herpes simplex virioris. Hum. Gene Ther. 9, 1543-1549 (1998).
74. Schellingerhout D, Rainov NG, Breakefield XO, Weissleder R: Quantitation of HSV mass distribution in a rodent brain tumor model. Gene Ther. 7, 1648-1655 (2000).